Olutasidenib
Last Updated: 04/28/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 46 publications
Differentiation Syndrome in Acute Myeloid Leukemia: Molecular Mechanisms, Clinical Spectrum, and Emerging Therapeutic Paradigms.
Journal: International journal of molecular sciences
Published: December 29, 2025
Matching-Adjusted Indirect Comparison of Olutasidenib and Ivosidenib in Isocitrate Dehydrogenase 1-Mutated Relapsed/Refractory Acute Myeloid Leukemia.
Journal: Advances in therapy
Published: December 17, 2025
The Care and Cure of the Leukemias in 2026.
Journal: American journal of hematology
Published: December 03, 2025
Olutasidenib: an Achilles' heel for IDH1-mutated MDS?
Journal: Blood advances
Published: October 20, 2025
Isocitrate Dehydrogenase Inhibitors in Acute Myeloid Leukemia.
Journal: Chemistry & biodiversity
Published: October 08, 2025
Chemotherapy in dedifferentiated chondrosarcoma: from neoadjuvant to palliative treatment options.
Journal: Critical reviews in oncology/hematology
Published: September 27, 2025
Outcomes of Patients With IDH1-Mutated Myeloid Neoplasms Treated With Olutasidenib.
Journal: Clinical lymphoma, myeloma & leukemia
Published: July 25, 2025
Olutasidenib for mutated IDH1 acute myeloid leukemia: final five-year results from the phase 2 pivotal cohort.
Journal: Journal of hematology & oncology
Published: July 21, 2025
Targeting of Mutant Isocitrate Dehydrogenase in Glioma: A Systematic Review.
Journal: Cancers
Published: July 11, 2025
Deep Dive into Targeted Therapies: Understanding IDH1-Mutant AML Treatments [Podcast].
Journal: Blood and lymphatic cancer : targets and therapy
Published: June 26, 2025
Advancing AML Treatment: Evidence-Based Regimens and Guideline Updates for Targeted Treatments in R/R AML [Podcast].
Journal: Blood and lymphatic cancer : targets and therapy
Published: June 19, 2025
Effectiveness of olutasidenib versus ivosidenib in patients with mutated isocitrate dehydrogenase 1 acute myeloid leukemia who are relapsed or refractory to venetoclax: the 2102-HEM-101 trial versus a US electronic health record-based external control arm.
Journal: Leukemia & lymphoma
Published: June 13, 2025
Last Updated: 04/28/2026